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Abstract. Neuroblastoma is the most common extracranial
solid tumor in children, accounting for up to 10% of all
childhood malignancies. Cellular heterogeneity is a hallmark
of this embryonal cancer, as distinct neural crest lineages can
be found within the same tumor sample. The aim of our study
was to investigate the presence of a subpopulation of immature
cells with features of cancer-like stem cells in 10 neuro-
blastoma cell lines. RT-PCR and flow cytometry were
performed in order to analyze different kinds of ‘stemness
genes’ such as: NESTIN (NES), CD133, SOX-2, BMI1, c-KIT,
MELK1, MUSASHI-1 (MSI1), FAS, CD44 and VIMENTIN
(VIM). In addition, glial and neuronal markers such as
NCAM1, GFAP and B-TUBULIN III (TUBB3) were
analyzed. Epigenetic changes within the CD133 (Prominin-1)
gene promoter were also analyzed. Neuroblastoma cell lines
showed a particular pattern of expression, suggesting the
presence of an immature cancer stem cell-like subpopulation.
The CD133 protein, commonly used to enrich putative cancer
propagating stem cell-like populations in different kinds of
solid tumors, presented a half-methylated DNA state in 7 of
the 12 neuroblastoma cell lines analyzed. An increase in
RNA and protein levels of CD133 was achieved following
demethylation by assays using 5-aza-2'-deoxycytidine
(5-Aza-dC). Since cancer stem cells are believed to be
responsible for tumor metastasis, escape from anticancer
therapies and disease relapse, their therapeutic targeting and
analysis is crucial in neuroblastoma. Moreover, the regulation
of CD133 by epigenetic changes may provide an innovative
mechanism of CD133 expression as its regulation still
remains unclear.
Introduction
Neuroblastoma, the most common extracranial solid tumor of
childhood, is believed to be caused by the primordial neural
crest derived cells that give rise to tumors of the sympathetic
nervous system and the adrenal gland (1). Evidence suggests
that malignancies can arise or be maintained by neural stem
cells (NSC) with the attributes of limitless replication and
self-renewal that can undergo a transformation to brain tumor
stem cells (BTSC) (2). The Notch, Sonic hedgehog, and
Wnt/ß-catenin developmental programs play a crucial part
in stem cell determination and renewal in diverse tissues.
Pathway dysregulation can be an important feature in
embryonal tumors such as neuroblastoma or medullo-
blastoma (3-5). The study of tumor stem cells in neuroblastoma
could be informative for the understanding of the biological
heterogeneity of this tumor that can behave in unpredictable
ways, from showing spontaneous regression to relentless
progression (6-8).
The expression of marker genes and proteins related to
BTSC and immature cells can give important information on
the presence of a population of this type of cells in neuro-
blastoma tumors or cell lines. CD133 (also named Prominin-1)
is a cell surface glycoprotein with 5 transmembrane domains
and two glycosylated extracellular loops with a molecular
weight of 97-120 kDa (9,10). CD133 was originally described
as a hematopoietic stem cell marker. It is expressed by
immature hematopoietic stem cells and is a marker for other
stem and progenitor cells including neural and embryonic
stem cells (11). It has been shown to be expressed in several
tumor tissues, including some hematologic neoplasias such
as leukemias and a number of solid tumors such as brain,
colon, ovarian and prostate neoplasias (12-15). At least five
alternative promoters with five alternative first exons have
been found for this gene. Different spliced transcripts have
been described and there appears to be a tissue-dependent
relationship with respect to the spliced isoforms (16). However,
the mechanisms for CD133 regulation of expression remain
unclear.
Epigenetic events lead to variations in gene expression.
DNA methylation patterns become important hallmarks of
tumor development and progression (17,18). Interestingly,
epigenetic changes on a promoter region of CD133 region
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have been described on glioblastoma, ovarian and colorectal
tumors (19-21). Although CD133 function on cell biology its
not clear, methylation status of this stem cell marker may be
an important feature for understanding the behaviour of cancer
stem cells in tumor biology.
The aim of our study was to investigate the presence of a
subpopulation of immature cells with features of cancer-like
stem cells on neuroblastoma cell lines. For this propose, we
chose different types of interesting immature marker genes
such as: NESTIN (NES), CD133, Sox-2, BMI1, c-KIT,
MELK1, MUSHASHI-1 (MSI1), FAS, CD44, and VIMENTIN
(VIM). The afore-mentioned proteins are those commonly
used for the analysis of a subpopulation of cancer stem cells,
but have not been fully investigated in neuroblastoma,
although some studies are showing increasing evidence of
their presence in this embryonal tumor (8,22,23). In addition,
other gene markers of mature cells such as NCAM1, GFAP
and B-TUBILIN III (TUBB3) were analyzed by RT-PCR and
flow cytometry. Epigenetic changes at CD133 were studied
as well as expression changes on RNA and protein level after
demethylation assays with 5-aza-2'-deoxycytidine (5-Aza-dC).
Materials and methods
Cell lines. Ten neuroblastoma cell lines were used in this
study: SKNDZ, SKNSH, SKNBe(2), SKNF1, and BE(2)C
were purchased from the American Type Culture Collection
(ATCC, Manassas, VA), and IMR-32, Kelly, SIMA, SH-
SY5Y, and MHHNB-11 were purchased from the Deutsche
Sammlung von Mikroorganismen und Zellkuturen GmbH
(DSMZ, Braunchsweig, Germany). All cell lines were cultured
in DMEM+L-Glutamax medium, supplemented with 10% fetal
bovine serum (FBS), 5% nonessential aminoacids (NEAA),
1% penicillin/streptomycin and 0.1% amphotericin B at 37˚C
with 5% CO2.
RNA isolation. RNA from the cell lines was purified using the
QuickPrep Total RNA extraction kit (Amersham Biosciences
Corporation, Piscataway, NJ, USA), following manufacturer's
instructions. RNA concentration was measured in a
SmartSpec™ Spectrophotometer (Bio-Rad, Hercules, CA,
USA) measuring absorbance at 260 nm.
cDNA synthesis and RT-PCR. Total RNA (1 μg) was reverse-
transcribed using the SuperScript™ II RNase H Reverse
Transcriptase (Invitrogen, Carlsbad, CA, USA), following the
manufacturer's instructions. RT-PCR for VIM, B-TUBB3,
CD44, CD133, GFAP, NES, NCAM1, MELK1, BMI1, C-KIT,
MSI1, FAS, SOX2, MYCN were performed on a Biometra®
thermocycler (T3) (Biometra, Göttingen, Germany). Approxi-
mately 100 ng of cDNA was amplified in a final volume of
25 μl. The reaction mix contained 2.5 μl 10X reaction buffer,
1.5-2.5 mM MgCl2, 0.2 mM of each dNTP, 5-10 pmol of
forward and reverse primers, 5% DMSO and one unit of
AmpliTaq Gold™ polymerase (Applied Biosystems, Foster
City, CA, USA). A denaturation step at 95˚C for 10 min was
followed by 30-40 cycles of amplification, alternating between
95˚C for 1 min, the corresponding annealing temperature for
each gene for 45 sec to 1 min, and 72˚C for 45 sec to 2 min.
A final extension step at 72˚C for 10 min was added. The
housekeeping gene for the transferring receptor (TFR, 3q29)
was used as an internal control of expression in all reactions.
PCR products were visualized in 2% agarose gels stained
with ethidium bromide at a final concentration of 0.1 μg/ml.
Primer sequences are detailed in Table I. All primers were
designed using Primer 3 software.
Analysis of protein expression by flow cytometry. Protein
expression of CD133, NES, MSI1, FAS, NCAM1, GFAP and
B-TUBB3 was performed by flow cytometry. One million
cells were incubated with CD133/1 (Miltenyi Biotec, 1:11),
FAS (Serotec, 1:100) and NCAM1 (Chemicon, 1:100) for
10-30 min at 4˚C. For FAS and NCAM1 detection, secondary
antibodies Cy2-donkey anti-mouse IgG (Jackson Immuno-
research) and FITC-donkey anti-rabbit IgG (Jackson Immuno-
research) were added, diluted 1:100 respectively and incubated
for 30 min at 4˚C. For NESTIN (Chemicon, 1:100),
MUSASHI-1 (Chemicon, 1:50), GFAP (Chemicon, 1:1000)
and B-TUBULIN III (Chemicon 1:100), we used the Fixation/
Permeabilization solution kit (BD Biosciences). Finally, cells
were analyzed in a Beckman Coulter EPIS XL cytometer. The
experiments were performed in triplicate.
DNA extraction. DNA from the cell lines was purified using
the Wizard® Genomic DNA purification kit (Promega
Corporation, Madison, WI, USA) according to the manu-
facturer's instructions.
DNA bisulfite treatment. Bisulfite modification of purified
genomic DNA was performed using the CpGenome™ DNA
modification kit (Chemicon® International Inc., Temecula,
CA, USA). Modified DNA was purified, eluted in 1 mM TE
(pH 8.0), and used immediately or stored at -80˚C for up to
six months. Normal genomic blood DNA and in vitro hyper-
methylated genomic DNA (Genome™ Universal Methylated
DNA, Chemicon International Inc.) were used as negative
and positive controls, respectively, for the methylation status
of DNA.
Methylation specific PCR (MSP). The promoter region of
CD133 was analyzed by MSP. The reaction was carried out in
a IQ5 Multicolor real-time PCR detection system (Bio-Rad)
using 40 ng of bisulfite modified DNA in a total volume of
25 μl. The reaction mix contained 2.5 μl 10X reaction buffer,
3-4 mM MgCl2, 0.2 mM of each dNTP, 5-10 pmol forward
and reverse primers, 5% DMSO and one unit of AmpliTaq
Gold polymerase (Applied Biosystems). Denaturation at
95˚C for 10 min initiated the reaction, followed by 38 cycles
of amplification. A final extension at 72˚C for 10 min
completed the reaction. PCR products were visualized with
ethidium bromide stained 2% agarose gels. The MSP primers
used are described elsewhere (21).
Melting curve analysis-based real-time methylation assay
(MCA-Meth). NCAM, TUBB3, VIMENTIN, NESTIN and
CD44 were analyzed by MCA-Meth using 3-6 ng of bisulfite
modified DNA in a final volume of 25 μl. The reaction
contained 12.5 μl of 2X IQTM SYBR Green Supermix (Bio-
Rad) and 2.5 pmol of each primer. Primers were designed
using MethPrimer software. Primer sequences are detailed in
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Table I. The reactions were heated at 95˚C in a first PCR step
for 10 min and then amplified for 45 cycles of 30 sec at 95˚C,
30 sec at the corresponding annealing temperature and 30 sec
at 72˚C. After the amplification step, the melting curve
analysis was carried out as follows: from 70˚C to 90˚C, 30 sec
at every 0.5˚C. Both the amplification step and the melting
curve were carried out in an IQ5 Multicolor real-time PCR
detection system (Bio-Rad).
5-aza-dC treatment. All cell lines were treated with 5 μM 5-
Aza-dC for 96 h. Approximately 4x105 to 6x105 cells were
grown in 25 cm2 flasks. During treatment the media was
changed daily. Real-time PCR was performed to check for
treatment-induced re-expression of CD133.
Real-time PCR. The expression of CD133 was assessed by
quantitative real-time PCR. The housekeeping gene for the
hypoxanthine phosphoribosyltransferase 1 (HPRT1) was
used as an internal control of expression in the reactions.
Primer sequences are detailed in Table I. The PCR reactions
were carried out in an IQ5 Multicolor real-time PCR
detection system (Bio-Rad). The reaction mix contained
12.5 μl 2X IQ™ SYBR Green supermix (Bio-Rad) and
12.5 pmol of forward and reverse primers. An initial
denaturation step at 95˚C for 10 min was followed by 30-35
cycles of amplification alternating between 94˚C for 30 sec,
64˚ annealing temperature for 30 sec, and 72˚C for 30 sec.
After the amplification step, the melting curve analysis was
carried out as follows: from 70˚C to 90˚C, 30 sec at every
0.5˚C. For the relative quantification, an efficiency corrected
quantification model was applied. The derivative ratio values
describe the relative expression change of the target gene
relative to the HPRT1 reference gene expression.
Results
RT-PCR expression of immature and differentiation markers.
We have determined RNA expression levels of several
immature and differentiation markers in 10 neuroblastoma
cell lines (Table II). Regarding the immature markers such as
CD133, NES and SOX2, generally used as stem cell markers,
we observed positive expression in most cell lines analyzed.
CD133 marker displayed a variable expression pattern; there
were several cell lines showing low expression [IMR-32,
SKNBE(2), SKNSH] or no expression (MHHNB11, SKNF1).
For BMI1, MSI1, CD44, MELK1, and VIM, all cell lines also
showed a widespread positive expression; these immature
markers are involved in several regulatory mechanisms
shared by NSC and BTSC. On the other hand, c-KIT was not
expressed in four cell lines [SKNF1, SHSYSY, KELLY,
BE(2)C] and presented low expression in two other cell lines
(MHHNB11, SKNSH). With regard to the differentiation
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Table I. Primer sequences for RT-PCR, MSP, MCA-Meth and qRT-PCR.a
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Name Forward (5'-3') Reverse (5'-3') ˚C
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
RT-PCR
VIMENTIN ACATTGAGATTGCCACCTACAG ACCGTCTTAATCAGAAGTGTCC 60
CD44 GGATTTTAGTTTTTGTTAGGTT CACCAAAACTTATCCATAATATC 58
CD133 GCTGATGTTGAAACTGCTTGAG TGGTGCCGTTGCCTTGG 64
C-KIT GCAGAAGCCACCAACACC GAGAGGACAGCGGACCAG 62
GFAP ACGCAGTATGAGGCAATGG CGGTAGTCGTTGGCTTCG 56
NESTIN GTGGCTCCAAGACTTCC GCACAGGTGTCTCAAGG 64
NCAM GAATGCCACCGCCAACC CAGCCTCGTCGTTCTTATCC 64
MELK-1 CACCTCACGGCTACCTATCTTC TCACTTGCGGTCACATCTTCC 64
BMI-1 ATTGTTCGTTACCTGGAGACC GGCAGCATCAGCAGAAGG 60
MUSASHI1 CCCTGGCTACACCTACC AGGCAGTGAGAGGAATGG 60
FAS GCCAATTCTGCCATAAGC TTGTCTGTGTACTCCTTCC 51
SOX2 GGCAGCTACAGCATGATGCAGGAC CTGGGTCATGGAGTACTGCAGG 65
TFR GTCAATGTCCCAAACGTCACCAGA ATTTCGGGAATGCTGAGAAAACAGACAGA 60
HPRT TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT 64
MCA-Meth
VIMENTIN TGAGGGATTTTTTATTTTTTTT TCTAAACTAAACTCACCCTAAA 60
TUBB3 GTTTATGGTAGTTTTTTGGTGGAG ATCCCAACTCCCTATCTTTTAACA 62
CD44 GGTTGAATTTAATGGTGTAAG TTTAAAAAATAACAACCCTCCC 64
NCAM GAAGGATATAGTGAGGTTTTTA TTTTACAAAATTATTTCCTACC 58
NESTIN GTATTTTGGGGAAGTAGGAATAGAG TCTAACCCACTAAAAATAAACAAAC 59
MSP
CD133 M GGCGGTTTTATATTTAGGTTTTCGTTC CGAACCCTCGAACGTAACG 63
CD133 U TTATTATGGTGGTTTTATATTTAGGTTTTTGTTTG ACTACAACCAAACCCTCAAACATAACA 63
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aAnneling temperature is shown in the right column.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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markers, the cell lines were positive for the neuronal marker
NCAM1, and negative for the glial marker GFAP.
Protein expression of immature and differentiation markers.
The percentage of cells expressing CD133, NES, MSI1,
NCAM1, GFAP and TUBB3 proteins in neuroblastoma cell
lines was analyzed by flow cytometry. We detected percentages
from 0 to 92%, depending on the cell line and marker analyzed
(Table III; Fig. 4). RT-PCR results correlated well with protein
expression, except for FAS in which the number of positive
cells was much lower than expected for the rest of cell lines.
The CD133 marker showed the most variable expression
pattern: low expression in three cell lines [SKNBE(2),
SKNSH, IMR-32], very high expression in two other cell
lines (SKNDZ, SIMA) and no expression in BE(2)C and
SKNF1. We found very high percentage of CD133 and NES
positive cells in several cell lines, but these markers did not
appear to be clearly coexpressed, although the two CD133
high expressing cell lines SKNDZ and SIMA presented a
correlation of both markers. On the other hand, regarding
MSI1, we did find positive correlation with CD133
expression. All cell lines displayed a clear neuronal
differentiation lineage, showing expression of neuronal
markers, NCAM1 and TUBB3, and no expression of glial
marker GFAP.
Promoter methylation of NCAM, VIMENTIN, NESTIN and
CD44 by MCA-Meth. Promoter methylation status of
immature gene markers NES, CD44 and VIM, and differen-
tiation gene marker NCAM1 was assessed by MCA-Meth or
MSP in the neuroblatoma cell lines. We did not find promoter
methylation of these markers.
Promoter methylation of CD133 by MSP. We analyzed the
promoter methylation status of a CpG island located between
the upstream alternative 5' UTR and exon 2 in 10 neuro-
blastoma cell lines (21) (Fig. 1). The CD133 promoter was
found to be unmethylated in 5 neuroblastoma cell lines: SIMA,
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Table II. Expression analysis of immature and differentation markers by RT-PCR in neuroblastoma cell lines.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
c-KIT BMI-1 MELK-1 VIM CD44 SOX2 CD133 NES MSI1 FAS NCAM1 GFAP
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
SKNF1 - + + + + + + + + + + +
SKNDZ + + + + + + + + + + + -
SHSY5Y - + + + + + - + + + -
KELLY - + + + + + + + + + + -
SIMA + + + + - + + + + + + -
SKNBE2C + + + + + + + + + + + -
BE2C - + + + + + - + + + + -
SKNSH + + + + + + + + + + + -
MHHNB11 + + + + + + - + + + + -
IMR-32 + + + + + - + + + + + -
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
+, Expression; -, No expression.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Table III. Analysis of protein level of CD133, NES, MSI-1, FAS, NCAM1, GFAP, and TUBB3 by flow cytometry in neuro-
blastoma cell lines.a
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Immature markers Differentiation markers
––––––––––––––––––––––––––––––––––––––––– –––––––––––––––––––––––––––––––––––
CD133 NES MSI1 FAS NCAM1 GFAP ß-Tub III
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
SKNF1 0 39.4 3 0 20.9 0 47.1
SKNDZ 28.3 53.4 87.8 0 53.5 0 75.5
SHSY5Y 2.7 63.2 11 5 7.9 0 24
KELLY 1.1 31.7 1.4 0 21.5 0 82.3
SIMA 33 62.8 84 4.2 57.3 0 81.3
SKNBE2 0.5 88 5.1 0 9.3 0 90
BE2C 0 17.5 7.3 0 13.9 0 46.1
SKNSH 8.2 92.3 0 4.7 3.7 0 83
MHHNB11 2.6 49.4 1 0 29.4 0 53.8
IMR-32 1.4 27 3 0 29 0 27
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aData are expressed as percentage of cells expressing a particular marker.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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SKNDZ, SKNSH, SKNBE(2) and MHHNB11. This group
contains cells expressing very high percentage of CD133
(SIMA, SKNDZ) or moderate levels [SKNSH, SKNBE(2),
MHHNB11]. The remaining cell lines analyzed [IMR-32,
SKNF1, KELLY, SHSYSY, and BE(2)C], displayed a half-
methylated promoter status, consistent with their low level of
CD133 expression.
Re-expression of CD133 at the RNA level. We performed a
demethylation assay using the demethylating agent, 5-aza-dC.
After treatment, we studied the expression change on RNA
level of the 5 half-methylated cell lines by real-time PCR.
We found an increase on CD133 RNA level in all half-
methylated cell lines. The fold change on RNA levels achieved
was diverse, depending on the cell line (Fig. 2A): 86.54%
(IMR-32), 8.93% (KELLY), 59.92% (SHSY5Y), 10%
(SKNF1), and 23.53% [BE(2)C].
Re-expression of CD133 at the protein level. For studying the
effect of the demethylation assay on CD133 protein expression,
the half-methylated cell lines were stained for CD133 marker
and flow cytometry was performed. We found a fold increase
in the surface protein expression ranging from 2 to 11% on
all the half methylated cell lines (Fig. 2B and 3). BE(2)C and
SKNF1 did not show an important increase on protein
expression.
Discussion
CD133 has been identified as a powerful marker for cancer
stem cells in several types of brain tumors such as medullo-
blastomas and glioblastomas (15). Cancer stem cells are
significantly enriched in CD133+ subpopulations derived
from all types of solid tumors (24). We found that most of
the neuroblastoma cell lines expressed the CD133 marker by
RT-PCR and flow cytometry. The analysis of CD133 at protein
level revealed the existence of different patterns of expression
in neuroblastoma cell lines as we found populations with
very high content of CD133+ cells and others with moderate
to low CD133 expression.
We decided to investigate whether epigenetic changes,
such as methylation of CpG islands from the CD133 promoter,
modified the expression of the gene in neuroblastoma cell
lines containing CD133+/- populations. Interestingly, we
found that CD133 was half-methylated in 50% of the neuro-
blastoma cell lines, and demethylation treatment with 5-Aza-
dC increased the CD133 expression at RNA and protein level
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Figure 1. Methylation status of CD133 promoter in neuroblatoma cell lines by MSP. (A) Half methylated cell lines. (B) Unmethylated cell lines. PCR
products for the unmethylated (U) and methylated (M) reaction were run on 2% agarose gels stained with ethidium bromide (0.1 μg/ml). IMD (in vitro
methylated DNA): positive control for M reaction; N (normal genomic DNA): positive control for U reaction.
Figure 2. Real-time PCR and flow cytometry analysis of CD133 expression
levels after 5-Aza-dC treatment. (A) Data represent the fold change on RNA
level of treated cells regarding untreated cells normalized for HPRT
housekeeping gene. (B) Percentage of CD133 positive cells in treated and
untreated cells.
A
B
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in most of the half-methylated cell lines. Yi et al (21) found
CD133 promoter methylation in glioblastomas and colorectal
tumors, and interestingly, the abnormal methylation status
was not found in normal brain or colon tissue, where CD133
is normally down-regulated during lineage commitment and
cell differentiation, showing that a cancer-specific epigenetic
change can be responsible for the regulation of CD133
expression. We also expanded our analysis of methylation
status to other stem cell markers, such as NES, CD44, VIM
and NCAM1 but we found that the promoter regions analyzed
were unmethylated.
With regard to NES protein analysis, we found high
levels of NES+ cells in most of the neuroblastoma cell lines,
but the percentage of CD133+ and NES+ cells was not
equivalent. A possible explanation is that NES expression
has been linked to MYCN amplification in neuroblastoma
cell lines (25).
We found that all neuroblastoma cell lines expressed high
levels of MELK1, a gene that has been found to be highly
expressed in NSC and malignant brain tumors such as
glioblastoma. MELK1 knockdown by siRNA resulted in
reducing the survival and producing the depletion of stem
cells isolated from GB in vitro (26). The implication of this
gene in neuroblastoma biology has not been described, but
there is increasing evidence that it is required for NSC self-
renewal (27).
With regard to the differentiation markers analyzed, all
neuroblastoma cell lines expressed the neuronal markers
NCAM1 and TUBB3, but none of them showed expression
of glial marker GFAP, which is in agreement with the neuro-
blastoma phenotype.
Among the other interesting markers analyzed, we must
highlight the expression of SOX2, BMI1 and MSI1. BMI1 is
required for the self-renewal capacity of several types of
normal and cancer stem cells, including neural crest stem
cells from the peripheral nervous system (28,29) and has
been previously shown to be important for neuroblastoma
tumorigenesis (30). The transcription factor SOX2 is an
essential gene due to its role in sustaining growth and self-
renewal of several stem cell types, both embryonic and adult
(31,32). In addition, it has been found to be expressed in a
variable percentage of cells in several malignant tissues
(33,34). We found that SOX2, not previously studied in
neuroblastoma, was expressed in most of the neuroblastoma
cell lines analyzed.
We found that all our cell lines expressed different levels
of MSI-1; interestingly, the highest percentage of expression
was identified on CD133 high expressing cell lines, SIMA
and SKNDZ. MSI1 is expressed predominantly in proliferating
multipotent neural precursor cells, but not in newly generated
postmitotic neurons (35). Nakano et al (36) examined MSI1
expression in human medulloblatomas and ependymomas,
suggesting that MSI1 could be a useful marker for
characterizing tumor heterogeneity and for examining the
analogy between normal NSCs and MSI1+ cells in pediatric
brain tumors.
Walton et al (8) performed an analysis of cellular hetero-
geneity in neuroblastoma cell lines. They found a population
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Figure 3. Flow cytometry analysis of CD133 expression after 5-Aza-dC demethylation assay. Increase of CD133 expressing cells in neuroblatoma cell lines
after 5-Aza-dC demethylation treatment. Following 96 h, treated and untreated cells were stained for CD133-PE (mouse IgG was used as isotype control)
and flow cytometry analysis was performed. The fluorescence of CD133 is depicted on the y axis, and the percentage of CD133+ cells (relative to the
corresponding isotype control) is shown on the left upper corner of each plot.
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called I-type cells (intermediate). These cells expressed
CD133, and showed increased tumorigenicity in soft agar
and in athymic mice. Other studies have demonstrated the
presence of a side population in 65% of neuroblastoma
tumors (37) together with the expression of several non-
neuronal, neuroblastic, and stem cell markers in different
isolated populations of neuroblastoma cell lines (23).
Brain tumor initiating cells often feature the CD133+/
musashi-1+/nestin+ or similar phenotypes. Our flow cytometry
analysis corroborates these findings as we observed this kind
of subpopulation in neuroblastoma cell lines. This group of
‘stemness genes’ can confer a phenotype responsible for
tumor metastasis, escape from anticancer therapies, and
ultimately, disease relapse. There is increasing evidence of
the presence of tumor stem cells in neuroblastoma cell lines
and tumors. Innovative strategies for targeting these cells are
vital for the improvement of patient outcome and are expected
to increase treatment success and prevent relapse. Further
characterization of neuroblastoma stem cells might be critical
for the improvement of anti-cancer therapeutics to target
cancer stem cell populations in human malignancies.
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